Samlyn Capital LLC Purchases 637,190 Shares of Celcuity Inc. (NASDAQ:CELC)

Samlyn Capital LLC lifted its position in shares of Celcuity Inc. (NASDAQ:CELC) by 92.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,326,953 shares of the company’s stock after purchasing an additional 637,190 shares during the period. Samlyn Capital LLC owned 3.78% of Celcuity worth $21,735,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Quest Partners LLC raised its position in Celcuity by 31.3% in the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after acquiring an additional 1,379 shares during the period. Commonwealth Equity Services LLC raised its position in Celcuity by 9.9% in the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after acquiring an additional 1,500 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in Celcuity by 7.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after acquiring an additional 1,600 shares during the period. BNP Paribas Financial Markets raised its position in Celcuity by 78.5% in the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock worth $193,000 after acquiring an additional 3,930 shares during the period. Finally, Pale Fire Capital SE raised its position in Celcuity by 38.4% in the fourth quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after acquiring an additional 4,000 shares during the period. 63.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

CELC has been the topic of several research reports. Stifel Nicolaus lowered their price objective on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. Leerink Partnrs raised shares of Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Lifesci Capital started coverage on shares of Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Celcuity currently has a consensus rating of “Buy” and a consensus target price of $28.67.

Celcuity Price Performance

CELC opened at $13.98 on Tuesday. The firm has a 50-day moving average price of $16.56 and a 200-day moving average price of $16.85. The company has a market capitalization of $490.71 million, a price-to-earnings ratio of -5.03 and a beta of 0.76. Celcuity Inc. has a twelve month low of $8.39 and a twelve month high of $22.19. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same quarter in the previous year, the firm posted ($0.66) EPS. Equities analysts expect that Celcuity Inc. will post -2.54 EPS for the current year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.